Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2011-08-16
2011-08-16
Ouspenski, Ilia (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Reexamination Certificate
active
07998478
ABSTRACT:
An antibody against AILIM (alternatively called JTT-1 antigen, JTT-2 antigen, ICOS and 8F4) was found to have a significant therapeutic effect on arthrosis, for example, rheumatoid arthritis and osteoarthritis, graft versus host disease, graft immune rejection, inflammation (hepatitis and inflammatory bowel diseases), diseased condition accompanied by the excessive production of an antibody against a foreign antigen triggered by immunological sensitization by the antigen.
REFERENCES:
patent: 5484892 (1996-01-01), Tedder et al.
patent: 5506126 (1996-04-01), Seed et al.
patent: 5521288 (1996-05-01), Linsley et al.
patent: 5747461 (1998-05-01), Markov
patent: 5770197 (1998-06-01), Linsley et al.
patent: 5914112 (1999-06-01), Bednar et al.
patent: 6075181 (2000-06-01), Kucherlapati
patent: 6440418 (2002-08-01), Black et al.
patent: 6531505 (2003-03-01), Xu et al.
patent: 6803039 (2004-10-01), Tsuji et al.
patent: 7030225 (2006-04-01), Tamatani et al.
patent: 7045615 (2006-05-01), Tamatani et al.
patent: 7112655 (2006-09-01), Tamatani et al.
patent: 7125551 (2006-10-01), Kroczek
patent: 7132099 (2006-11-01), Kroczek
patent: 7166283 (2007-01-01), Tsuji et al.
patent: 7196175 (2007-03-01), Tamatani et al.
patent: 7217792 (2007-05-01), Tamatani et al.
patent: 7226909 (2007-06-01), Tamatani et al.
patent: 7247612 (2007-07-01), Tamatani et al.
patent: 7259147 (2007-08-01), Tamatani et al.
patent: 7259247 (2007-08-01), Kroczek
patent: 7279560 (2007-10-01), Tamatani et al.
patent: 7294473 (2007-11-01), Tamatani et al.
patent: 7438905 (2008-10-01), Suzuki et al.
patent: 7465445 (2008-12-01), Tezuka et al.
patent: 2002/0151685 (2002-10-01), Tamatani et al.
patent: 2002/0156242 (2002-10-01), Tamatani et al.
patent: 2002/0164697 (2002-11-01), Coyle et al.
patent: 2003/0083472 (2003-05-01), Tamatani et al.
patent: 2004/0131608 (2004-07-01), Watanabe
patent: 2004/0229790 (2004-11-01), Tezuka et al.
patent: 2008/0199466 (2008-08-01), Tsuji et al.
patent: 13320/99 (1999-04-01), None
patent: 19821060 (1999-04-01), None
patent: 0 984 023 (2000-03-01), None
patent: 1 125 585 (2001-08-01), None
patent: 5-72204 (1993-03-01), None
patent: 11-228442 (1999-08-01), None
patent: 2000-154151 (2000-06-01), None
patent: WO 95/33770 (1995-12-01), None
patent: WO 97/26912 (1997-07-01), None
patent: WO 98/11909 (1998-03-01), None
patent: WO 98/19706 (1998-05-01), None
patent: WO 98/30232 (1998-07-01), None
patent: WO 98/37415 (1998-08-01), None
patent: WO 98/38216 (1998-09-01), None
patent: WO 98/45331 (1998-10-01), None
patent: WO 98/52606 (1998-11-01), None
patent: WO 99/15553 (1999-04-01), None
patent: WO 00/19988 (2000-04-01), None
patent: WO 00/46240 (2000-08-01), None
patent: WO 00/67788 (2000-11-01), None
patent: WO 01/08700 (2001-02-01), None
patent: WO 01/12658 (2001-02-01), None
patent: WO 01/15732 (2001-03-01), None
patent: WO 01/18022 (2001-03-01), None
patent: WO 01/21796 (2001-03-01), None
patent: WO 01/32675 (2001-05-01), None
patent: WO 01/64704 (2001-09-01), None
patent: WO 01/87981 (2001-11-01), None
patent: WO 02/44364 (2002-06-01), None
patent: WO 02/070010 (2002-09-01), None
patent: WO 02/076504 (2002-10-01), None
Carlesso et al., “Depletion of inducible co-stimulator (ICOS) bearing T cells inhibits expansion of T follicular helper cells (TFH) and prevents disease in a graft versus host mouse model of scleroderma” Poster Presentation, American College of Rheumatology, 2009 Annual Scientific Meeting, Oct. 19, 2009.
Carlesso et al., “Targeted depletion of inducible co-stimulator (ICOS) bearing T cells prevents disease in a graft versus host model of scleroderma” Poster Presentation, 9thInternational Conference on Systemic Lupus Erythematosus, Jun. 25, 2010.
Cook et al., “The human immunoglobulin VHrepertoire,”Immunology Today(1995) 16(5):237-42.
Faggioni et al., “Determination of the minimum anticipated biological level (MABEL) for an ADCC-enhanced inducible co-stimulator (ICOS) monoclonal antibody for the treatment of autoimmune diseases” Poster Presentation, Annual Congress of the European League Against Rheumatism, Jun. 2010.
Ghosh et al. “Ulcerative colitis” (2000) BMJ. 320(7242):1119-23.
Hanauer et al. “Management of Crohn's disease in adults” (2001) Am J Gastroenterol. 96(3):635-43.
Koh et al., “A screening method of SH2 domain ligands and blockers using a solid phase binding” (1997) Cancer Lett. 120(1):1-7.
Mendez et al. “Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice” (1997) Nat Genet. 15(2):146-56.
Mittereder et al., “ICOS is critical for follicular helper T cells (TFH)-mediated maintenance of germinal center B cells in non human primates” Poster Presentation, American College of Rheumatology, 2008 Annual Scientific Meeting, Oct. 28, 2008.
Mittereder, “ICOS is critical for T follicular helper cell-mediated maintenance of germinal center B cells in non-human primates” FASEB Summer Research Conference—Autoimmunity, Jul. 2, 2009.
Soderlind et al., “Domain libraries: Synthetic diversity for de novo design of antibody V-regions,”Gene(1995) 160(2):269-72.
Takai et al. “Epitope analysis and primary structures of variable regions of anti-human FcepsilonRI monoclonal antibodies, and expression of the chimeric antibodies fused with human constant regions” Biosci Biotechnol Biochem. (2000) 64(9):1856-67.
Taylor et al. “Unraveling Functions of ICOS Bearing T Cells: New Insights about Treating Autoimmune Disorders” Poster Presentation, Keystone Symposia on Tolerance and Autoimmunity, Feb. 21-26, 2010.
van der Merwe et al., “CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics,”Journal of Experimental Medicine(1997) 185(3):393-403.
Abbas, “T-cell stimulation: an abundance of B7s,” Nat Med. 5(12):1345-6 (1999).
Aicher et al., “Characterization of Human Inducible Costimulator Ligand Expression and Function,” J. Immunol., 164(9):4689-4696 (2000).
Attwood T., Science 2000, 290:471-473.
Bajorath “A molecular model of inducible costimulator protein and three-dimensional analysis of its relation to the CD28 family of T cell-specific costimulatory receptors,” J. Mol. Model. 5:169-176 (1999).
Beier et al., “Induction, binding specificity and function of human ICOS,” Eur. J. Immunol., 30(12):3707-3717 (2000).
Bensimon et al., “Human lupus anti-DNA autoantibodies undergo essentially primary V kappa gene rearrangements,” EMBO J. 13(13):2951-62 (1994).
Brodie et al., “LICOS, a primordial costimulatory ligand?,” Curr. Biol., 10(6):333-336 (2000).
Buonfiglio et al., “Characterization of a novel human surface molecule selectively expressed by mature thymocytes, activated T cells and subsets of T cell lymphomas,” Eur. J. Immunol., 29(9)2863-2874 (1999).
Buonfiglio et al., “The T cell activation molecule H4 and the CD28-like molecule ICOS are identical,” Eur. J. Immunol. 30(12):3463-3467 (2000).
Cameron “Recent advances in transgenic technology” Molecular Biotechnology 7:253-65 (1997).
Campbell et al., “Separable effector T cell populations specialized for B cell help or tissue inflammation,” Nat Immunol. 2(9):876-81 (2001).
Chambers, “The expanding world of co-stimulation: the two-signal model revisited,” Trends in Immunology, 22(4):217-223 (2001).
Chapoval et al., “B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production,” Nat Immunol. 2(3):269-74 (2001).
Cocks et al. “A novel receptor involved in T-cell activation,” Nature, 376:260-263 (Jul. 20, 1995).
Coyle et al., “The CD28-Related Molecule ICOS is Required for Effective T Cell-Dependent Immune Responses,” Immunity 13(1):95-105 (2000).
Dong et al,, “B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion,&#
Abe Ryo
Tezuka Katsunari
Watanabe Yoshihiro
Fish & Richardson P.C.
Japan Tobacco Inc.
Ouspenski Ilia
LandOfFree
Pharmaceutical composition for treating immune diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition for treating immune diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition for treating immune diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2633298